June 15, 2018 – MONTREAL, QUEBEC – Relevium Technologies Inc. (TSX.V:  “RLV”,  OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce it has put into production 920,000 soft-gels each of its Cardio-Metabolic Syndrome and Dry-Eye Syndrome formulations containing Provinal® Omega 7.

Highlights

  • Relevium puts into production 920,000 soft gels using Provinal® is a patented ultra-purified Omega 7 fatty acid blend
  • CardiaPro with Provinal® is shown to support cardio metabolic health by reducing insulin resistance, hepatic fat accumulation and acute and chronic inflammation
  • VisionPro with Provinal® is also shown to improve the quality of tears and with its exclusive formulation, supports complete eye health
  • First formulations with North American exclusivity for online sales through Amazon, Walmart and Native Website.

On December 6, 2017 the Company announced an exclusivity agreement with Tersus Life Sciences to formulate and distribute exclusive products with Provinal® Omega 7. The Company has put into production its first two formulations aimed at servicing two critical markets, Heart and Eye Health.

The two formulations will be marketed through BioGanix® Platinum and Bioganix® Gold labels throughout its online presence in its Native Website, Social Media, Amazon and Walmart and they are expected to be available for sale in September of this year. 

Aurelio Useche CEO Stated: “The start of the production of these unique products represent a critical milestone for Relevium and its Bioganix® brand” Mr. Useche stated further: “We have been positively overwhelmed with the professionalism and excellence demonstrated by the team of scientists and formulators at Tersus Life Sciences and we are proud to be able to provide a superior and unique formulation with their patented Provinal® Omega 7 fish oil”.

About Provinal® Omega 7

Provinal® Omega 7 is a novel, patented and clinically-substantiated monounsaturated fatty-acid ingredient targeting the prevention and reversal of dyslipidemia, and cardio-metabolic disorders. Provinal® Omega 7 is a naturally-occurring highly purified monounsaturated fatty acid. Preclinical and clinical evidence has demonstrated a broad range of benefits bridging the treatment gap in highly prevalent disorders with special emphasis on lipid management.

Omega 7 (purified palmitoleic acid) oil of palmitate can potentially help in the fight against diabetes, metabolic syndrome, and atherosclerosis. In this 4-minute video, Dr. Michael F. Roizen, frequent contributor on the Dr. Oz show and Chairman of the Wellness Institute of The Cleveland Clinic, explores the beneficial effects of Provinal® on the management of atherosclerosis, its causes and consequences: heart disease, stroke, memory loss, impotence, and wrinkling.

Purified Omega 7 has been shown to decrease insulin resistance, decrease hepatic fat accumulation, and decrease acute and chronic inflammation – with no known side effects. More information can be found on the Tersus Life Sciences webpage at tersuslifesciences.com

About Relevium Technologies

Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

On Behalf of the Board of Directors

RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO

For more information about this press release:

Tel: +1.888.528.8687

RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn